The stock of Chemours Co (NYSE:CC) is a huge mover today! The stock increased 5.54% or $0.84 during the last trading session, hitting $16. About 3.65M shares traded hands or 52.08% up from the average. Chemours Co (NYSE:CC) has risen 209.39% since February 26, 2016 and is uptrending. It has outperformed by 198.96% the S&P500.
The move comes after 5 months positive chart setup for the $2.89B company. It was reported on Sep, 30 by Barchart.com. We have $21.76 PT which if reached, will make NYSE:CC worth $1.04B more.
Analysts await Chemours Co (NYSE:CC) to report earnings on November, 3. They expect $0.26 earnings per share, down 35.00% or $0.14 from last year’s $0.4 per share. CC’s profit will be $46.96 million for 15.38 P/E if the $0.26 EPS becomes a reality. After $0.27 actual earnings per share reported by Chemours Co for the previous quarter, Wall Street now forecasts -3.70% negative EPS growth.
Chemours Co (NYSE:CC) Ratings Coverage
Out of 8 analysts covering Chemours (NYSE:CC), 3 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 38% are positive. Chemours has been the topic of 16 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The company was upgraded on Friday, August 7 by JP Morgan. Argus Research upgraded Chemours Co (NYSE:CC) on Wednesday, August 10 to “Buy” rating. The stock of Chemours Co (NYSE:CC) earned “Neutral” rating by Citigroup on Thursday, August 11. As per Friday, August 7, the company rating was upgraded by JP Morgan. The firm has “Sell” rating given on Tuesday, August 18 by UBS. As per Monday, July 27, the company rating was initiated by Susquehanna. The company was downgraded on Tuesday, February 16 by Jefferies. The stock has “Neutral” rating given by Citigroup on Monday, April 18. Citigroup initiated the shares of CC in a report on Friday, August 14 with “Neutral” rating. As per Tuesday, August 9, the company rating was maintained by UBS.
According to Zacks Investment Research, “Chemours Company is involved in chemical business. It operating segment consists of Titanium Technologies, Fluoroproducts and Chemical Solutions. Titanium Technologies segment produces titanium dioxide and premium white pigment. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins. Chemical Solutions segment provides industrial and specialty chemicals. The company’s brand consists of Teflon(R), Ti-Pure(R), Krytox(R) Viton(R), Opteon(R) and Nafion(R). Chemours Company is headquartered in Wilmington.”
More notable recent Chemours Co (NYSE:CC) news were published by: Fool.com which released: “Chemours Co Surges After New Jury Verdict” on July 08, 2016, also Valuewalk.com with their article: “Chemours Co (CC) â€œMost Morally And Financially Bankrupt Companyâ€ Ever: Citron …” published on June 02, 2016, Valuewalk.com published: “Chemours Co (CC) Starts To Rally After Tanking On Wednesday” on July 07, 2016. More interesting news about Chemours Co (NYSE:CC) were released by: Fool.com and their article: “Here’s Why Chemours Co Stock Popped Today” published on February 24, 2016 as well as Investorplace.com‘s news article titled: “Why Chemours Co (CC), Petroleo Brasileiro SA Petrobras (ADR) (PBR) and Polycom …” with publication date: July 08, 2016.
CC Company Profile
The Chemours Company, incorporated on February 18, 2014, is a well-known provider of performance chemicals. The Firm operates through three divisions: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Company’s Titanium Technologies segment produces titanium dioxide (TiO2). The Company’s Fluoroproducts segment provides fluoroproducts, such as refrigerants and industrial fluoropolymer resins. The Company’s Chemical Solutions segment provides industrial and specialty chemicals used in gold production, oil refining, agriculture, industrial polymers and other industries. The Firm operates approximately 30 production facilities located in over 10 countries and serves a range of end markets in over 130 countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.